{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:25:30Z","timestamp":1793064330149,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C33589\/A19727"],"award-info":[{"award-number":["C33589\/A19727"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C33589\/A28284"],"award-info":[{"award-number":["C33589\/A28284"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"The National Institute for Health Research Biomedical Research Centre for cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","award":["RRCOER-Jun24\/100006"],"award-info":[{"award-number":["RRCOER-Jun24\/100006"]}],"id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","award":["A28724"],"award-info":[{"award-number":["A28724"]}],"id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002669","name":"Elekta AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.radonc.2026.111363","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:41:05Z","timestamp":1767685265000},"page":"111363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1016-9841","authenticated-orcid":false,"given":"Sian","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6432-7136","authenticated-orcid":false,"given":"Charlotte","family":"Cherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7113-9243","authenticated-orcid":false,"given":"Joan","family":"Chick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1632-9623","authenticated-orcid":false,"given":"Mathijs G.","family":"Dassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-636X","authenticated-orcid":false,"given":"Shermarke","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7542-0622","authenticated-orcid":false,"given":"Trina","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8473-8166","authenticated-orcid":false,"given":"Francesca","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-3349","authenticated-orcid":false,"given":"Adam","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4351-8136","authenticated-orcid":false,"given":"Simeon","family":"Nill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Oelfke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-4149","authenticated-orcid":false,"given":"Floris","family":"Pos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtuza","family":"Saifuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyne","family":"Westley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uulke A","family":"van der Heide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9714-2782","authenticated-orcid":false,"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111363_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111363_b0010","unstructured":"NATCAN. National Prostate Cancer Audit State of the Nation Report. 2025."},{"key":"10.1016\/j.radonc.2026.111363_b0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111363_b0020","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0025","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111363_b0035","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","article-title":"Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study","volume":"82","author":"Arrayeh","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111363_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110535","article-title":"Intra-prostatic recurrences after radiotherapy with focal boost: Location and dose mapping in the FLAME trial","volume":"201","author":"Menne Guricov\u00e1","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ijrobp.2019.11.402","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: efficacy and toxicity in the DELINEATE trial","volume":"106","author":"Murray","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111363_b0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0060","doi-asserted-by":"crossref","unstructured":"Manne-Guricova K. 10 year outcomes of FLAME trial. In: Focal Boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 10-year Results. Vienna; 2025.","DOI":"10.1016\/S0167-8140(25)00510-9"},{"key":"10.1016\/j.radonc.2026.111363_b0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.brachy.2020.10.009","article-title":"HDR brachytherapy as monotherapy for prostate cancer: a systematic review with meta-analysis","volume":"20","author":"Viani","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2026.111363_b0070","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiation Oncol*Bio*Phys"},{"key":"10.1016\/j.radonc.2026.111363_b0075","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111363_b0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijrobp.2020.01.010","article-title":"Diminishing returns from ultrahypofractionated radiation therapy for prostate cancer","volume":"107","author":"Vogelius","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111363_b0085","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctro.2019.04.001","article-title":"Adaptive radiotherapy: the Elekta unity MR-linac concept","volume":"18","author":"Winkel","year":"2019","journal-title":"Clin Trans Radiation Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.616291","article-title":"MR-guided radiotherapy for prostate cancer","volume":"10","author":"Tocco","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0095","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41391-021-00417-1","article-title":"Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level","volume":"25","author":"Oerther","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.radonc.2026.111363_b0100","unstructured":"Dassen, Mathijs G. Primary endpoint analysis of the phase II DESTINATION-MRL trial for patients with intermediate-risk prostate cancer."},{"key":"10.1016\/j.radonc.2026.111363_b0105","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3389\/fonc.2020.01328","article-title":"The MOMENTUM study: an international registry for the evidence-based introduction of MR-guided adaptive therapy","volume":"10","author":"de Mol van Otterloo","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0110","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2026.111363_b0115","first-page":"35","article-title":"Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: initial clinical experiences and assessment of delivered doses compared to a C-arm linac","volume":"23","author":"Dunlop","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.radonc.2015.04.012","article-title":"Prostate tumor delineation using multiparametric magnetic resonance imaging: inter-observer variability and pathology validation","volume":"115","author":"Steenbergen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0125","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/jmri.26933","article-title":"Histopathological features of MRI\u2010Invisible regions of prostate cancer lesions","volume":"51","author":"Van Houdt","year":"2020","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2026.111363_b0130","unstructured":"U.S. Department of health and human services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017."},{"key":"10.1016\/j.radonc.2026.111363_b0135","unstructured":"University of Michigan. Expanded Prostate Cancer Index Composite."},{"key":"10.1016\/j.radonc.2026.111363_b0140","unstructured":"British Association of Urological Surgeons. International Prostate Symptoms Score (I-PSS)."},{"key":"10.1016\/j.radonc.2026.111363_b0145","unstructured":"The University of Michigan. Scoring Instructions for the Expanded Prostate cancer Index Composite Short Form (EPIC-26). 2002."},{"key":"10.1016\/j.radonc.2026.111363_b0150","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2026.111363_b0155","doi-asserted-by":"crossref","unstructured":"Dassen M. Primary endpoint analysis of the phase II DESTINATION-MRL trial for patients with favorable intermediate-risk prostate cancer. In: Radiotherapy and Oncology.Vol 206. Vienna, Austria; 2025.","DOI":"10.1016\/S0167-8140(25)01037-0"},{"key":"10.1016\/j.radonc.2026.111363_b0160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.prro.2024.10.009","article-title":"Simulation of focal boosting in online adaptive MRI-guided SBRT for patients with locally advanced prostate cancer with seminal vesicle involvement","volume":"15","author":"Dassen","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.10.015","article-title":"DESTINATION 1 preliminary dosimetry analysis","volume":"38","author":"Cooper","year":"2025","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0170","doi-asserted-by":"crossref","first-page":"S2009","DOI":"10.1016\/S0167-8140(25)01262-9","article-title":"2750 Exploring predictive factors for late urinary toxicity after prostate SBRT: findings from the PACE-B study","volume":"206","author":"Ratnakumaran","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0175","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2017.12.022","article-title":"Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial","volume":"127","author":"Monninkhof","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109713","article-title":"From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial","volume":"185","author":"De Cock","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0185","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2018.02.029","article-title":"Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial","volume":"127","author":"Quon","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111363_b0190","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/cam4.2966","article-title":"Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results","volume":"9","author":"Zilli","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2026.111363_b0195","doi-asserted-by":"crossref","unstructured":"Cooper S, Westley RL, Biscombe K, et al. HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025:S0360-3016(25)00476\u20136.","DOI":"10.1016\/j.ijrobp.2025.05.008"},{"key":"10.1016\/j.radonc.2026.111363_b0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.39769","article-title":"Comparison of response to definitive radiotherapy for localized prostate cancer in black and white men","volume":"4","author":"Ma","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2026.111363_b0205","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cncr.33224","article-title":"Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration","volume":"127","author":"McKay","year":"2021","journal-title":"Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:24:19Z","timestamp":1781511859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"alternative-id":["S0167814026000010"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111363","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111363"}}